Robert J Hamilton1, Keyue Ding2, Juanita M Crook3, Christopher J O'Callaghan2, Celestia S Higano4, David P Dearnaley5, Eric M Horwitz6, S Larry Goldenberg7, Mary K Gospodarowicz8, Laurence Klotz9. 1. Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: rob.hamilton@uhn.ca. 2. Canadian Cancer Trials Group (CCTG), Queen's University, Kingston, ON, Canada. 3. University of British Columbia, Kelowna, BC, Canada; British Columbia Cancer Agency, Kelowna, BC, Canada. 4. University of Washington and Fred Hutchinson Cancer Research Centre, Seattle, WA, USA. 5. The Institute for Cancer Research and Royal Marsden Hospital, London, UK. 6. Fox Chase Cancer Centre, Philadelphia, PA, USA. 7. Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada. 8. Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada. 9. Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Abstract
BACKGROUND: Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report positive results, with a few specifically examining statins and androgen deprivation therapy (ADT). OBJECTIVE: To perform a post hoc secondary analysis of a randomised controlled trial (RCT) of men initiating ADT to examine the association between statin use and outcomes. DESIGN, SETTING, AND PARTICIPANTS: Patients with prostate-specific antigen (PSA) >3 ng/ml >1 yr following primary/salvage radiotherapy were enrolled in an RCT of intermittent androgen deprivation (IAD) versus continuous ADT (NCT00003653). Baseline and on-study statin use was modelled as a time-dependent covariate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was overall survival. Models were adjusted for age, time from radiotherapy to ADT, baseline PSA, and prior ADT. RESULTS AND LIMITATIONS: Of 1364 patients, statin users (585; 43%) were younger (72.7 vs 73.8 yr, p = 0.001) and less likely to have PSA >15 ng/ml (20% vs 25%, p = 0.04). After a median follow-up of 6.9 yr, statin use was associated with reduced overall (hazard ratio [HR]: 0.64; 95% confidence interval [CI] 0.53-0.78, p < 0.001) and PCa-specific (HR: 0.65, 95% CI 0.48-0.87, p = 0.004) mortality. Statin users had 13% longer time to castration resistance, but this did not reach statistical significance (p = 0.15). As an exploratory endpoint, in the IAD arm, statin users had longer time off treatment (median: 0.85 vs 0.64 yr, p = 0.06). Limitations include potential for residual confounding between statin users and nonusers, and confounding by indication. CONCLUSIONS: In men treated with ADT following primary or salvage radiotherapy, statin use was associated with improved overall and PCa-specific survival. In patients treated with IAD, statin use was associated with a trend towards longer time off treatment. A prospective trial of statins in men commencing ADT is warranted. PATIENT SUMMARY: We found a favourable association between statin use and survival outcomes in patients initiating androgen deprivation therapy.
BACKGROUND: Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report positive results, with a few specifically examining statins and androgen deprivation therapy (ADT). OBJECTIVE: To perform a post hoc secondary analysis of a randomised controlled trial (RCT) of men initiating ADT to examine the association between statin use and outcomes. DESIGN, SETTING, AND PARTICIPANTS: Patients with prostate-specific antigen (PSA) >3 ng/ml >1 yr following primary/salvage radiotherapy were enrolled in an RCT of intermittent androgen deprivation (IAD) versus continuous ADT (NCT00003653). Baseline and on-study statin use was modelled as a time-dependent covariate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was overall survival. Models were adjusted for age, time from radiotherapy to ADT, baseline PSA, and prior ADT. RESULTS AND LIMITATIONS: Of 1364 patients, statin users (585; 43%) were younger (72.7 vs 73.8 yr, p = 0.001) and less likely to have PSA >15 ng/ml (20% vs 25%, p = 0.04). After a median follow-up of 6.9 yr, statin use was associated with reduced overall (hazard ratio [HR]: 0.64; 95% confidence interval [CI] 0.53-0.78, p < 0.001) and PCa-specific (HR: 0.65, 95% CI 0.48-0.87, p = 0.004) mortality. Statin users had 13% longer time to castration resistance, but this did not reach statistical significance (p = 0.15). As an exploratory endpoint, in the IAD arm, statin users had longer time off treatment (median: 0.85 vs 0.64 yr, p = 0.06). Limitations include potential for residual confounding between statin users and nonusers, and confounding by indication. CONCLUSIONS: In men treated with ADT following primary or salvage radiotherapy, statin use was associated with improved overall and PCa-specific survival. In patients treated with IAD, statin use was associated with a trend towards longer time off treatment. A prospective trial of statins in men commencing ADT is warranted. PATIENT SUMMARY: We found a favourable association between statin use and survival outcomes in patients initiating androgen deprivation therapy.
Authors: Joseph Longo; Stephen J Freedland; Linda Z Penn; Robert J Hamilton Journal: Prostate Cancer Prostatic Dis Date: 2022-06-29 Impact factor: 5.554
Authors: Jiun-Hung Geng; Anna Plym; Kathryn L Penney; Mark Pomerantz; Lorelei A Mucci; Adam S Kibel Journal: Prostate Cancer Prostatic Dis Date: 2022-01-24 Impact factor: 5.554
Authors: Virginia S Hahn; Kathleen W Zhang; Lova Sun; Vivek Narayan; Daniel J Lenihan; Bonnie Ky Journal: Circ Res Date: 2021-05-13 Impact factor: 17.367
Authors: Abdulmajeed Aydh; Reza Sari Motlagh; Mishari Alshyarba; Keiichiro Mori; Satoshi Katayama; Nico Grossmann; Pawel Rajwa; Hadi Mostafai; Ekaterina Laukhtina; Benjamin Pradere; Fahad Quhal; Frederik König; Peter Nyirady; Pierre I Karakiewicz; Martin Haydter; Shahrokh F Shariat Journal: Cent European J Urol Date: 2021-12-06
Authors: Youquan Li; Whee Sze Ong; Ma Than Than Shwe; Nelson Ling Fung Yit; Sheriff Zhan Hong Quek; Eric Pei Ping Pang; Wen Shen Looi; Wen Long Nei; Michael Lian Chek Wang; Melvin Lee Kiang Chua; Terence Wee Kiat Tan; Eu Tiong Chua; Choon Ta Ng; Jeffrey Kit Loong Tuan Journal: Cardiooncology Date: 2022-03-14
Authors: Aino Siltari; Jarno Riikonen; Juha Koskimäki; Tomi Pakarainen; Otto Ettala; Peter Boström; Heikki Seikkula; Andres Kotsar; Teuvo Tammela; Mika Helminen; Paavo V Raittinen; Terho Lehtimäki; Mikkel Fode; Peter Østergren; Michael Borre; Antti Rannikko; Timo Marttila; Arto Salonen; Hanna Ronkainen; Sven Löffeler; Teemu J Murtola Journal: BMJ Open Date: 2022-04-29 Impact factor: 2.692
Authors: Paavo V H Raittinen; Heimo Syvälä; Teuvo L J Tammela; Merja R Häkkinen; Pauliina Ilmonen; Seppo Auriola; Teemu J Murtola Journal: EBioMedicine Date: 2021-06-16 Impact factor: 8.143